Genzyme announced today that the FDA has granted marketing approval for Mozobil™ (plerixafor injection), a drug intended to be used in combination with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells to the bloodstream for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma and multiple myeloma. More› Please click here for full prescribing information.

Genzyme, the Broad Institute of Harvard and MIT, and Medicines for Malaria Ventures (MMV) today announced that its scientists presented several posters, in addition to an oral presentation, this week at the American Society of Tropical Medicine and Hygiene (ASTMH) in New Orleans, La. The research focused on progress these organizations have made through their ongoing collaboration to develop improved treatment therapies for malaria. More›

Genzyme Corporation today announced that the FDA’s Orthopaedic and Rehabilitation Devices Advisory Committee voted unanimously (5 – 0) in favor of approval without conditions of Synvisc-One™ (hylan G-F 20).  More›